TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05996302

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relocation to sea level
Description: Relocation to sea level by bus and stay for 2 days

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relocation to sea level
Description: Relocation to sea level by bus and stay for 2 days
Study: NCT05690867

Intervention type: OTHER
Group type: OTHER
Intervention: Starting with volume controlled ventilation and changing the ventilation mode every 20 minutes
Description: group 1 starts with volume controlled ventilation and we take three consecutive measurements in twenty minutes , after twenty minutes we change the ventilation mode to pressure controlled ventilation after letting washout we take three consecutive measurements at pressure controlled ventilation and we will repeat this protocol during surgery

Intervention type: OTHER
Group type: OTHER
Intervention: Starting with pressure controlled ventilation and changing the ventilation mode every 20 minutes
Description: group 2 starts with pressure controlled ventilation and we take three consecutive measurements in twenty minutes , after twenty minutes we change the ventilation mode to volume controlled ventilation after letting washout we take three consecutive measurements at volume controlled ventilation and we will repeat this protocol during surgery
Study: NCT05826561

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Childhood Asthma Passive Digital Marker
Description: A childhood asthma Passive Digital Marker (PDM) is an ML algorithm that is able to retrieve and synthesize pre-existing passively collected mother/child dyad prognostic data in digital electronic health record (EHR) to provide an objective and quantifiable marker of a child's risk (probability) and associated pathophysiological phenotype to inform clinician decision-making at point-of-care.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Childhood Asthma Passive Digital Marker
Description: A childhood asthma Passive Digital Marker (PDM) is an ML algorithm that is able to retrieve and synthesize pre-existing passively collected mother/child dyad prognostic data in digital electronic health record (EHR) to provide an objective and quantifiable marker of a child's risk (probability) and associated pathophysiological phenotype to inform clinician decision-making at point-of-care.
Study: NCT05896267

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Masimo INVSENSOR00061
Description: Masimo INVSENSOR00061 will be used to measure noninvasive SpO2 (Oxygen Saturation ) in blood .
Study: NCT05811234

Intervention type: DRUG
Intervention: CAL/BDP PAD Cream
Description: As provided in real-world clinical practice.
Study: NCT06105905

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy futures (Futuros Saludables)
Description: The developed intervention will be delivered in a workshop format by facilitators, over 8 sessions for teens and 2 sessions for parent/guardian(s). Feedback on delivery mode (virtual, in-person, or hybrid) during the co-development sessions. If in-person/hybrid is suggested, feedback will be elicited about preferred location (e.g., a local community center, sports club, etc.). Participants will complete sessions, in either Spanish or English depending on participants' preference, using video conference tools. After the delivery of the intervention, facilitators will take field notes and complete a debriefing questionnaire to assess practicality and fidelity. Parent/guardians will complete a 5 minute pre- and post- intervention survey. Teens will complete a 15 minute survey pre-intervention, immediately post-intervention, three-month, six-month, and twelve-month post-intervention. Surveys will assess acceptability and risk behaviors.
Study: NCT05580445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT-707
Description: Focal Adhesion Kinase (FAK) inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Programmed Death 1(PD-1) antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: nucleoside inhibitor
Study: NCT06307925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HC010
Description: HC010 Q2W/28d intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HC010
Description: HC010 Q2W/28d intravenous infusion
Study: NCT06595030

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Lighting Intervention
Description: The TLI will allow researchers to use a light source that will control how the circadian system is stimulated and provide the participants with options as to how the light treatment will be delivered.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Control Lighting Intervention
Description: The TLI will allow researchers to use a light source that will not stimulate the circadian system and provide the participants with options as to how the light treatment will be delivered.
Study: NCT05984420

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LimpiAD 2,5% plus cream
Description: A topical formulation that contains Hyaluronic Acid conjugated with a bacterial wall fragment of Cutibacterium species (HAc-40) and an emollient base. LimpiAD exerts its post-biotic action through the seizure/ trapping and inactivation of catabolites and / or toxins produced by S. aureus as well as protecting the hydrolipidic film, especially in case of dryness, itching, and, in conditions of altered microbiome

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vehicle
Description: Vehicle of LimpiAD 2.5 % plus cream which has the qualities of an emollient technically enriched with active ingredients known for their use in AD (plus emollient) - having the same ingredients of LimpiAD 2.5% Plus but without the HAc-40 component.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Emollient
Description: Standard emollient used as neutral control, having only a moisturizing and skin barrier action, which represents the basic standard treatment (basic therapy) of atopic dermatitis according to the European Guidelines.
Study: NCT06449196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Investigational product HIV Env Mosaic immunogens MOS1SIP, MOS2SIP, M3SIP8 and Monophosphoryl lipid A liposomes (MPLA-5) adjuvant (IM)
Description: HIV Env Mosaic immunogens MOS1SIP, MOS2SIP, M3SIP8 and Monophosphoryl lipid A liposomes (MPLA-5) adjuvant (IM) administered via bolus dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: : Investigational product HIV Env Mosaic immunogens MOS1SIP, MOS2SIP, M3SIP8 and Monophosphoryl lipid A liposomes (MPLA-5) adjuvant (IM)
Description: HIV Env Mosaic immunogens MOS1SIP, MOS2SIP, M3SIP8 and Monophosphoryl lipid A liposomes (MPLA-5) adjuvant (IM) administered via fractionated dosing
Study: NCT05646524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NM8074
Description: NM8074 will be administered as an intravenous infusion. Doses will be administered over a treatment period of 13 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NM8074
Description: NM8074 will be administered as an intravenous infusion. Doses will be administered over a treatment period of 13 weeks.
Study: NCT06044701

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hologram Distraction Technique
Description: Hologram fan application during blood collection process

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bubble Machine Distraction Technique
Description: Bubble machine application during blood collection
Study: NCT05726188

Intervention type: PROCEDURE
Intervention: Colonic resection
Description: Elective or urgent colonic resection; minimally-invasive or open surgery; completion surgery for endoscopically resected pT1 colon cancer with high risk features
Study: NCT00710216

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamivudine
Description: 100 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telbivudine
Description: 600 mg/day
Study: NCT05318742

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laser
Description: Endolaser photocoagulation during PPV

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laser
Description: Endolaser photocoagulation during PPV
Study: NCT02422368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone + ASTED
Description: ASTED tablet: Twice daily for 6 months~Methylprednisolone:~Methylprednisolone tablet of 50 and 5 mg, company....) 1mg/kg for the first 2 weeks, 0.8mg/kg for 2 weeks, 0.7 mg/kg for 2 weeks, and then tapering off the methylprednisolone in 6 weeks (total duration of 12 weeks) by 8-10 mg per week. For example, a patient with 75 kg weight will receive 75 mg for 2 weeks, 60 mg for 2 weeks, 52.5 mg for 2 weeks, and then decreasing by 8-10 mg per week for 6 weeks. The dose regiment will be written and handed to the patient on the first visit and will be monitored during the follow ups.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methylprednisolone +Placebo
Description: Placebo: twice daily~Methylprednisolone:~Methylprednisolone tablet of 50 and 5 mg, company....) 1mg/kg for the first 2 weeks, 0.8mg/kg for 2 weeks, 0.7 mg/kg for 2 weeks, and then tapering off the methylprednisolone in 6 weeks (total duration of 12 weeks) by 8-10 mg per week. For example, a patient with 75 kg weight will receive 75 mg for 2 weeks, 60 mg for 2 weeks, 52.5 mg for 2 weeks, and then decreasing by 8-10 mg per week for 6 weeks. The dose regiment will be written and handed to the patient on the first visit and will be monitored during the follow ups.
Study: NCT05960630

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MIRRORS Protocol
Description: Diagnostic laparoscopic assessment proceeding to either robotic (if considered appropriate following laparoscopic assessment) or open Interval cytoreductive surgery with conversion to open at any point should this be required to remove all visible disease.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Open Cytoreductive Surgery
Description: Extended midline incision. Open surgical approach to interval cytoreductive surgery with the aim of removing all visible disease.
Study: NCT05213728

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VXA-G1.1-NN
Description: Norovirus GI.1 Norwalk VP1 Vaccine (VXA-G1.1-NN) E1/E3-Deleted Replication-Defective Recombinant Adenovirus 5 with Adjuvant Oral Tablet Vaccine.
Study: NCT04974632

Intervention type: PROCEDURE
Group type: OTHER
Intervention: localization
Description: small, deep or ground-glass opacity (GGO) lung tumor, Mobile 3D C-arm CT assisted pre-operative localization, video-assisted thoracic surgery(VATS)
Study: NCT04334083

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comparison of biomarkers of stress
Description: Emergency will be followed during a night shift and the rest day et during a day shift and the rest day. They will be observed by a medical externship student. We will assess the role of expertise and habituation to stressful emergency situations.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comparison of biomarkers of stress
Description: Emergency will be followed during a night shift and the rest day et during a day shift and the rest day. They will be observed by a medical externship student. We will assess the role of expertise and habituation to stressful emergency situations.
Study: NCT05873218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ephedrine
Description: The intervention will be up to two 7.5 mg doses of ephedrine given after the placement of a combined spinal epidural with 25 mcg intrathecal fentanyl timed 3 and 15 minutes after intrathecal opiate administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline Placebo
Description: Placebo will be administered at matching rate.
Study: NCT05783557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clevidipine Butyrate Injectable Emulsion
Description: intravenous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cleviprex®
Description: intravenous injection
Study: NCT06247891

Intervention type: PROCEDURE
Group type: OTHER
Intervention: ECS Group
Description: Patients underwent endoscopic and endocytoscopic evaluations.
Study: NCT04080895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine
Description: Artemether-lumefantrine on Day 0, 1 and 2 Washout period: more than 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amodiaquine
Description: Amodiaquine on Day 0, 1 and 2 Washout period: more than 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amodiaquine
Description: Amodiaquine on Day 0, 1 and 2 Washout period: more than 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine
Description: Artemether-lumefantrine on Day 0, 1 and 2 Washout period: more than 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine + Amodiaquine
Description: Artemether-lumefantrine + Amodiaquine on Day 0, 1 and 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine + Amodiaquine
Description: Artemether-lumefantrine + Amodiaquine on Day 0, 1 and 2
Study: NCT05462509

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bCPAP with blenders
Description: The intervention device is a low-cost bCPAP kit which includes two fixed-ratio oxygen blenders that do not require a source of pressurized air. These simple and inexpensive devices sit in-line from the oxygen source and dilute the flowing stream of oxygen with room air, obviating the need for a pressurized source of air. The oxygen may be supplied from either high-pressure sources or low-pressure sources such as oxygen concentrators. Each of the two blenders are single plastic parts, injection moulded from a biocompatible, medical-grade polyethylene resin. No electricity is required for the blenders to provide a stable and constant mix of air and oxygen over the full range of clinically relevant pressure and flows for newborns.
Study: NCT05827029

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Preopertive drink
Description: * Group C: will receive a carbohydrate drink of 400 ml (50 g of glucose prepared by nutrition division, same appearance and containing bottles of water)~* Group W: will receive water 400 ml (prepared by nutrition division, Songklanagarind hospital, same appearance and containing bottles of carbohydrate drink) In both groups, the received 400-mL drink was consumed within 5 minutes.~* Before drinking, baseline data (gastric residual volume, POCT glucose, degree of hunger, and thirst) will be evaluated.~* Gastric ultrasound will be performed by the same Radiologist on each participant at 0, 30, 60, 90, 120 minutes~* after drinking to evaluate the gastric residual volume and time to empty gastric antrum.~* POCT glucose and degree of hunger and thirst are also assessed again at 120 minutes after drinking.~* After completing one type of drinking, participants will be appointed again after 1 week later for doing the same protocol with another drinking.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Preopertive drink
Description: * Group C: will receive a carbohydrate drink of 400 ml (50 g of glucose prepared by nutrition division, same appearance and containing bottles of water)~* Group W: will receive water 400 ml (prepared by nutrition division, Songklanagarind hospital, same appearance and containing bottles of carbohydrate drink) In both groups, the received 400-mL drink was consumed within 5 minutes.~* Before drinking, baseline data (gastric residual volume, POCT glucose, degree of hunger, and thirst) will be evaluated.~* Gastric ultrasound will be performed by the same Radiologist on each participant at 0, 30, 60, 90, 120 minutes~* after drinking to evaluate the gastric residual volume and time to empty gastric antrum.~* POCT glucose and degree of hunger and thirst are also assessed again at 120 minutes after drinking.~* After completing one type of drinking, participants will be appointed again after 1 week later for doing the same protocol with another drinking.
Study: NCT05743465

Intervention type: OTHER
Intervention: No Intervention
Description: As this is an observational study, no intervention will be administered in this study.

Intervention type: OTHER
Intervention: No Intervention
Description: As this is an observational study, no intervention will be administered in this study.

Intervention type: OTHER
Intervention: No Intervention
Description: As this is an observational study, no intervention will be administered in this study.
Study: NCT05813509

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Organoid culture
Description: Tumor like organ is a kind of organ cultured from tissues of tumor patients, which is a small tumor growing in a culture dish. Compared with the traditional two-dimensional culture system, the most important feature of this technological innovation is that it can directly use the patient's own tissue to culture organ like cells. At the same time, these organ like cells can well replicate some key characteristics of the primary tumor and retain the pathological form and biological mechanism of the patient's tissue
Study: NCT04683510

Intervention type: OTHER
Group type: OTHER
Intervention: Navigation - Study Specific - Researcher Voice
Description: The intervention is delivered over the telephone

Intervention type: OTHER
Group type: OTHER
Intervention: Navigation - Study Specific - Cancer Survivor Voice
Description: The intervention is delivered over the telephone

Intervention type: OTHER
Group type: OTHER
Intervention: Navigation - Research General - Researcher Voice
Description: The intervention is delivered over the telephone

Intervention type: OTHER
Group type: OTHER
Intervention: Navigation - Research General - Cancer Survivor Voice
Description: The intervention is delivered over the telephone

Intervention type: OTHER
Group type: OTHER
Intervention: Brochure - Study Specific - Researcher Voice
Description: The invention is mailed to the participant in a brochure.

Intervention type: OTHER
Group type: OTHER
Intervention: Brochure - Study Specific - Cancer Survivor Voice
Description: The invention is mailed to the participant in a brochure.

Intervention type: OTHER
Group type: OTHER
Intervention: Brochure - Research General - Researcher Voice
Description: The invention is mailed to the participant in a brochure.

Intervention type: OTHER
Group type: OTHER
Intervention: Brochure - Research General - Cancer Survivor Voice
Description: The invention is mailed to the participant in a brochure.
Study: NCT05412771

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hysteroscopy
Description: Samples will be collected from consenting patients undergoing a surgical hysteroscopy for medical purposes
Study: NCT05901818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous induced neural stem cell-derived DA precursor cells
Description: The autologous induced neural stem cell-derived DA precursor cells will be stereotactically implanted into the striatum of PD patients.
Study: NCT05518318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLS-010
Description: Participants receive GLS-010 240mg intravenously (IV) on Day 1, Q2W

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy of Investigator's choice
Description: Chemotherapy administered as assessed as appropriate by the investigator in accordance with the local guideline, including but not limited to DHAP,GEMOX, ESHAP , ICE , IGEV and GVD
Study: NCT04812847

Intervention type: DIAGNOSTIC_TEST
Intervention: Identification of MDR characteristics
Description: Identification of MDR in culture media, followed by amplification of related genes from the bacterial isolates

Intervention type: DIAGNOSTIC_TEST
Intervention: Identification of MDR characteristics
Description: Identification of MDR in culture media, followed by amplification of related genes from the bacterial isolates
Study: NCT05391789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulinastatin
Description: Patients would be given 400000 or 800000units of ulinastatin (specification: 100000 units / vial) dissolved in 50 ml of 0.9% normal saline intravenously for at least 1 hour, once every 8 hours. It is evaluated by the attending doctor every day. When the patient does not have systemic inflammatory response syndrome (SIRS), halve the dose and continue to use it for 2 days, with a total course of treatment of at least 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulinastatin
Description: Patients would be given 400000 or 800000units of ulinastatin (specification: 100000 units / vial) dissolved in 50 ml of 0.9% normal saline intravenously for at least 1 hour, once every 8 hours. It is evaluated by the attending doctor every day. When the patient does not have systemic inflammatory response syndrome (SIRS), halve the dose and continue to use it for 2 days, with a total course of treatment of at least 3 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients would be given 50 ml of 0.9% normal saline intravenously for at least 1 hour once every 8 hours.It is evaluated by the attending doctor every day. When the patient does not have systemic inflammatory response syndrome (SIRS), continue to use it for 2 days, with a total course of treatment of at least 3 days.
Study: NCT05652088

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Description: Colonoscopy is a procedure where an instrument called colonoscope is inserted through the rectum to look at the entire internal surface of the intestine. Participants will be placed on a stretcher on the left side. A colonoscope will be advanced into the colon and into the terminal ileum. The entire procedure should take approximately 40 minutes